Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors

Annals of Surgical Oncology

Volumn 17, Issue 4, 2010, Pages 1194-1202

  Chien, Wen Pin ^a   Wong, Ruey Hong ^a   Cheng, Ya Wen ^a   Chen, Chih Yi ^b   Lee, Huei ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MESSENGER RNA; MITHRAMYCIN; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952090036     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0853-2     Document Type: Article

References (37)

1. D Menendez A Inga JJ Jordan MA Resnick 2007 Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson Oncogene 26 2191 2201 10.1038/sj.onc.1210277 1:CAS:528:DC%2BD2sXjs1yqt7w%3D 17401428 (Pubitemid 46536639)
2. Y Tomizawa T Kohno T Fujita, et al. 1999 Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma Oncogene 18 1007 1014 10.1038/sj.onc.1202384 1:CAS:528: DyaK1MXhsVyit7s%3D 10023676 (Pubitemid 29086277)
3. SA Ahrendt Y Hu M Buta, et al. 2003 p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study J Natl Cancer Inst 95 961 970 1:CAS:528:DC%2BD3sXltFygtLY%3D 12837832 (Pubitemid 36896713)
4. HH Nelson M Wilkojmen CJ Marsit KT Kelsey 2005 TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis 26 1770 1773 10.1093/carcin/bgi125 1:CAS:528:DC%2BD2MXhtVWnt7nL 15905205 (Pubitemid 41487993)
5. JH Schiller S Adak RH Feins, et al. 2001 Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy J Clin Oncol 19 448 457 1:CAS:528:DC%2BD3MXhtVektL4%3D 11208838 (Pubitemid 32112858)
6. SL Harris AJ Levine 2005 The p53 pathway: Positive and negative feedback loops Oncogene 24 2899 2908 10.1038/sj.onc.1208615 1:CAS:528: DC%2BD2MXjtlehs7c%3D 15838523 (Pubitemid 40638098)
7. F Toledo GM Wahl 2006 Regulating the p53 pathway: In vitro hypotheses, in vivo veritas Nat Rev Cancer 6 909 923 10.1038/nrc2012 1:CAS:528: DC%2BD28Xht1Clsr3E 17128209 (Pubitemid 44862676)
8. GL Bond W Hu EE Bond, et al. 2004 A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 591 602 10.1016/j.cell.2004.11.022 1:CAS:528:DC%2BD2cXhtVGls7bF 15550242 (Pubitemid 39535748)
9. G Koutsodontis I Tentes P Papakosta A Moustakas D Kardassis 2001 Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein J Biol Chem 276 29116 29125 10.1074/jbc.M104130200 1:CAS:528:DC%2BD3MXlvFSqsbw%3D 11384995 (Pubitemid 37452000)
10. H Hirata Y Hinoda N Kikuno K Kawamoto Y Suehiro Y Tanaka R Dahiya 2007 MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma Clin Cancer Res 13 4123 4129 10.1158/1078-0432.CCR-07-0609 1:CAS:528:DC%2BD2sXnvVCiu7Y%3D 17634539 (Pubitemid 47108171)
11. S Cattelani R Defferrari S Marsilio, et al. 2008 Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: Results of a pilot study on 239 patients Clin Cancer Res 14 3248 3253 10.1158/1078-0432.CCR-07-4725 1:CAS:528:DC%2BD1cXmslygs7w%3D 18519749
12. I Gryshchenko S Hofbauer M Stoecher, et al. 2008 MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia J Clin Oncol 26 2252 2257 10.1200/JCO.2007.11.5212 1:CAS:528:DC%2BD1cXntVOltr8%3D 18467716
13. N Ohmiya A Taguchi N Mabuchi A Itoh Y Hirooka Y Niwa H Goto 2006 MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis J Clin Oncol 24 4434 4440 10.1200/JCO.2005.04.1459 1:CAS:528:DC%2BD28XhtVyisrrI 16983111 (Pubitemid 46630981)
14. RS Heist W Zhou LR Chirieac, et al. 2007 MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer J Clin Oncol 25 2243 2247 10.1200/JCO.2006.08.8914 1:CAS:528:DC%2BD2sXnsVShtbc%3D 17538168 (Pubitemid 46954650)
15. M Sanchez-Carbayo ND Socci T Kirchoff N Erill K Offit BH Bochner C Cordon-Cardo 2007 A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer Clin Cancer Res 13 3215 3220 10.1158/1078-0432.CCR-07-0013 1:CAS:528: DC%2BD2sXmtVajuro%3D 17545525 (Pubitemid 46944904)
16. V Galic J Willner M Wollan, et al. 2007 Common polymorphism in TP53 and MDM2 and relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas Genes Chromosomes Cancer 46 239 247 10.1002/gcc.20407 1:CAS:528:DC%2BD2sXpt1KksQ%3D%3D 17171684 (Pubitemid 46155319)
17. JL Ko YW Cheng SL Chang JM Su CY Chen H Lee 2000 MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer Int J Cancer 89 265 270 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N 1:STN:280:DC%2BD3czitFCitg%3D%3D 10861503 (Pubitemid 30430743)
18. M Higashiyama O Doi K Kodama, et al. 1997 MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation Br J Cancer 75 1302 1308 1:STN:280:DyaK2s3pvF2jsw%3D%3D 9155050 (Pubitemid 27179820)
19. A Slack Z Chen R Tonelli M Pule L Hunt A Pession, et al. 2005 The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma Proc Natl Acad Sci USA 102 731 736 10.1073/pnas.0405495102 1:CAS:528: DC%2BD2MXis1CqsL8%3D 15644444 (Pubitemid 40282734)
20. JL Ko MC Chiao SL Chang P Lin JC Lin GT Sheu H Lee 2002 A novel p53 mutant retained functional activity in lung carcinomas DNA Repair (Amst) 1 755 762 10.1016/S1568-7864(02)00094-0 1:CAS:528:DC%2BD38Xnsl2gtbY%3D
21. GL Bond KM Hirshfield T Kirchhoff, et al. 2006 MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 66 5104 5110 10.1158/0008-5472.CAN-06-0180 1:CAS:528:DC%2BD28XksF2isr0%3D 16707433 (Pubitemid 43844932)
22. CC Huang YW Cheng MC Chen YS Lin MC Chou H Lee 2006 Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers Environ Mol Mutagen 47 527 532 10.1002/em.20222 1:CAS:528:DC%2BD28XhtV2ht7%2FO 16721749 (Pubitemid 44291165)
23. M Phelps M Darley JN Primrose JP Blaydes 2003 p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells Cancer Res 63 2616 2623 1:CAS:528:DC%2BD3sXjsleht70%3D 12750288 (Pubitemid 36605204)
24. X Zhang X Miao Y Guo, et al. 2006 Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer Hum Mutat 27 110 117 10.1002/humu.20277 16287156 (Pubitemid 43042973)
25. Z Hu H Ma D Lu, et al. 2006 Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population Int J Cancer 118 1275 1278 10.1002/ijc.21463 1:CAS:528:DC%2BD28XhsFektrY%3D 16152608 (Pubitemid 43185617)
26. GL Bond AJ Levine 2007 A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans Oncogene 26 1317 1323 10.1038/sj.onc.1210199 1:CAS:528:DC%2BD2sXitVKhs7s%3D 17322917 (Pubitemid 46328460)
27. GL Bond C Menin R Bertorelle P Alhopuro LA Aaltonen AJ Levine 2006 MDM2 SNP309 accelerates colorectal tumour formation in women J Med Genet 43 950 952 10.1136/jmg.2006.043539 1:CAS:528:DC%2BD2sXhtVOgtrs%3D 16825430 (Pubitemid 46080193)
28. JA Royds B Iacopetta 2006 p53 and disease: when the guardian angel fails Cell Death Differ 13 1017 1026 10.1038/sj.cdd.4401913 1:CAS:528: DC%2BD28Xks1Ortbs%3D 16557268 (Pubitemid 43753492)
29. P Lianes I Orlow ZF Zhang MR Oliva AS Sarkis VE Reuter C Cordon-Cardo 1994 Altered patterns of MDM2 and TP53 expression in human bladder cancer J Natl Cancer Inst 86 1325 1330 10.1093/jnci/86.17.1325 1:CAS:528:DyaK2cXmsFaksbw%3D 8064890 (Pubitemid 24276794)
30. H Saito S Tsujitani S Oka M Ikeguchi M Maeta N Kaibara 2002 The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation Ann Surg Oncol 9 450 456 10.1007/BF02557267 12052755 (Pubitemid 34625804)
31. F Courjal M Cuny C Rodriguez, et al. 1996 DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours Br J Cancer 74 1984 1989 1:CAS:528:DyaK2sXotFKhsA%3D%3D 8980401 (Pubitemid 27007146)
32. B Tanner JG Hengstler S Laubscher, et al. 1997 mdm 2 mRNA expression is associated with survival in ovarian cancer Int J Cancer 74 438 442 10.1002/(SICI)1097-0215(19970822)74:4<438::AID-IJC13>3.0.CO;2-5 1:CAS:528:DyaK2sXlslKjurg%3D 9291435 (Pubitemid 27400165)
33. GL Bond W Hu A Levine 2005 A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect Cancer Res 65 5481 5484 10.1158/0008-5472.CAN-05-0825 1:CAS:528:DC%2BD2MXlslOru7k%3D 15994915 (Pubitemid 40911143)
34. K Oda H Arakawa T Tanaka, et al. 2000 p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53 Cell 102 849 862 10.1016/S0092-8674(00)00073-8 1:CAS:528:DC%2BD3cXmvFSht7w%3D 11030628
35. C Menin MC Scaini GL De Salvo, et al. 2006 Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status J Natl Cancer Inst 98 285 288 1:CAS:528:DC%2BD28Xhs1Skt7w%3D 16478747 (Pubitemid 43264712)
36. D Polsky K Melzer C Hazan, et al. 2002 HDM2 protein overexpression and prognosis in primary malignant melanoma J Natl Cancer Inst 23 1803 1806 (Pubitemid 36004356)
37. MC Tammemagi JR McLaughlin SB Bull 1999 Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers Cancer Epidemiol Biomarkers Prev 8 625 634 1:STN:280: DyaK1MzlsFWmtw%3D%3D 10428201